Advanced search
Showing results 7741 to 7760 on 8962 in total
-
Pharmacogenetics and responders to a therapy: Theoretical background and practical problems
J.-P. Boissel, François Gueyffier, Michel Cucherat, G. Bricca
-
Absolute benefit number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit?
Behrouz Kassai, François Gueyffier, J.-P. Boissel, F. Boutitie, Michel Cucherat
-
How should therapeutic information be transferred to users?
J.-P. Boissel, M. Haugh, M. Fardeheb, Patrice Nony, François Gueyffier, N. Strang
-
Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments
J.-P. Boissel, François Gueyffier, F. Boutitie, S. Pocock, R. Fagard
-
Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome
J.-G. Wang, J.A. Staessen, S. Franklin, R. Fagard, François Gueyffier
-
The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests
Behrouz Kassai, N.R. Shah, A. Leizorovicz, Michel Cucherat, François Gueyffier, J.-P. Boissel
-
Estimation of attributable burden of disease: authors' reply
François Gueyffier, Jm. Wright
-
Safety of computerized drug management: a case report
K.-A. Nguyen, T. Vial, François Gueyffier, S. Marignier, P. Cochat, Behrouz Kassai
-
The lower the better: Does simplicity lead to absurdity?
François Gueyffier, Jm. Wright
-
Cardiovascular Risk Stratification in Decision Support Systems: A Probabilistic Approach. Application to pHealth
H. Atoui, J. Fayn, François Gueyffier, P. Rubel
-
The JIKEI trial
F. Boutitie, François Gueyffier, Jm. Achard
-
Does a change in angiotensin-II-formation caused by antihypertensive drugs affect the risk of stroke ? A meta-analysis of trials according to treatment with potentially different effects on angiotensin-II
F. Boutitie, R. Oprisiu, J.M. Achard, H. Mazouz, J. Wang, F.H. Messerli, François Gueyffier, A. Fournier
-
Severe myoclonic epilepsy in infancy: A systematic review and a meta-analysis of individual patient data
Behrouz Kassai, C. Chiron, S. Augier, Michel Cucherat, E. Rey, François Gueyffier, R. Guerrini, J. Vincent, O. Dulac, Gérard Pons
-
Meta-analysis of continuous outcomes combining individual patient data and aggregate data
Rd. Riley, Pc. Lambert, Ja. Staessen, J. Wang, François Gueyffier, L. Thijs, F. Boutitie
-
New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear
J.-P. Boissel, Michel Cucherat, P. Nonyc, Sylvie Chabaud, François Gueyffier, Jm. Wright, M. Lièvre, A. Leizorovicz
-
SCORE should be preferred to Framingham to predict cardiovascular death in French population
I. Marchant, J-P. Boissel, Behrouz Kassai, T. Bejan-Angoulvant, J. Massol, C. Vidal, E. Amsallem, F. Naudin, P. Galan, S. Czernichow, Patrice Nony, François Gueyffier
-
Recueil systématique et actif des evènements indésirables médicamenteux chez les enfants admis aux urgences pédiatriques
F. Planchamp, K.-A. Nguyen, T. Vial, S. Nasri, E. Javouhey, Y. Gillet, B. Ranchin, F. Villard, D. Floret, P. Cochat, François Gueyffier, Behrouz Kassai
-
Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.
Albert Fournier, Roxana Oprisiu-Fournier, Jean-Marie Serot, Olivier Godefroy, Jean-Michel Achard, Sébastien Faure, Hakim Mazouz, Mohamed Temmar, Adriana Albu, Régis Bordet, Olivier Hanon, François Gueyffier, Jiguang Wang, Sandra Black, Naoyuki Sato
-
Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials
T. Bejan-Angoulvant, M. Saadatian-Elahi, Jm. Wright, E.B. Schron, Lh. Lindholm, R. Fagard, J.A. Staessen, François Gueyffier
-
Blood pressure lowering in the oldest old: a step toward abandoning arbitrary blood pressure targets
François Gueyffier, M.I. Perez, Jm. Wright, I. Marchant, V.M. Musini, Theodora Bejan-Angoulvant